137 results on '"Moliterno, David"'
Search Results
2. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
3. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
4. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
5. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
6. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
7. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis
8. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
9. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry
10. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
11. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)
12. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
13. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
14. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites
15. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry
16. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)
17. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry
18. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
19. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry
20. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
21. LB-9 | Repeated Coronary Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
22. Immediate vs Delayed Coronary Angiography for Out-of-Hospital Cardiac Arrest: A Meta-Analysis of Randomized Controlled Trials
23. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
24. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
25. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy
26. Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions
27. Meta-Analysis of Long-Term Outcomes for Drug-Eluting Stents Versus Bare-Metal Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction
28. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension
29. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial
30. Coronary Physiology Assessment: On Becoming Faster, Friendlier, and a Better Guiding Companion
31. In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
32. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
33. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
34. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography
35. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry
36. Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] Registry)
37. Contribution of Bleeding and Thromboembolic Events to In-Hospital Mortality Among Patients With Thrombocytopenia Treated With Heparin
38. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
39. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
40. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
41. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
42. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
43. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
44. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
45. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
46. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
47. In Unstable Angina or Non–ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?
48. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians
49. JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
50. The Influence of Peripheral Arterial Disease on Outcomes: A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.